Abstract P299: Associations of Inflammation Biomarkers with Sleep Disordered Breathing in the Multi-Ethnic Study of Atherosclerosis (MESA)
Background: Sleep disordered breathing, defined using obstructive apnea/hypopnea index (OAHI), is associated with cardiovascular risk factors and clinical disease. Inflammation may be a mediator of this relationship. We examined associations of inflammation biomarkers, C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen and serum albumin, with OAHI in MESA.
Methods: 1,864 MESA participants (857 men; 684 White, 528 Black, 435 Hispanic, 217 Chinese; mean age 59 years) were included in analyses. We used adjusted regression models to examine associations of individual biomarker levels at exam 1 (2000-02) with OAHI determined by full in-home polysomnography conducted at exam 5 (2010-12). Model 1 was age, sex and race adjusted; model 2 was model 1, education, diabetes, hypertension, dyslipidemia (total/HDL cholesterol > 5 or use of lipid-lowering medications), smoking, waist circumference and estrogen use adjusted. OAHI was categorized as <5, 5-15, 15-30 and >30.
Results: Regression results are summarized in Table. In Model 1, geometric mean levels of CRP, IL-6, fibrinogen and albumin were associated with higher OAHI compared to those with OAHI <5. In Model 2, only associations with albumin remained statistically significant. The attenuation appeared to be due to adjustment for waist circumference as models adjusted only for age, sex, race and waist circumference produced results similar to fully adjusted models. Associations did not differ by sex or race (non-blacks versus blacks).
Conclusions: Among diverse, apparently healthy adults, OAHI was associated with CRP, IL-6 and fibrinogen levels measured ten years earlier. Associations were attenuated adjusting for waist circumference, indicating that obesity may mediate the association between these biomarkers and OAHI. A novel association between OAHI and serum albumin, independent of obesity, was observed, suggesting the potential usefulness of this highly bioactive molecule in studies of sleep apnea.
Author Disclosures: N.S. Jenny: None. D. Benkeser: None. D. Duprez: None. P. Zee: None. M.L. Daviglus: None. J. Dinkler: None. K.E. Watson: None. S. Redline: None.
- © 2015 by American Heart Association, Inc.